Invesco JPX-Nikkei 400 UCITS ETF - EUR Hedged Acc (NS4E)

https://getmysocial.com/tina9

I asked ChatGPT the following:

"Why is BBUL shares selling for almost twice the price of regular BB shares?"

This catches a lot of people by surprise, but the price of BBUL is not supposed to equal—or even be close to—the price of BB stock.

The ETF sponso

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

Is ZNOG A Good Investment? An Honest Assessment

https://i.postimg.cc/dV8XpJmX/New-To-ZNOG-Fig1-License-Map.jpg
(Figure 1. The Megiddo-Jezreel License — the single asset on which this entire company depends. ~75,000 acres. License 434 base term expires September 13, 2026.)

Substitute 9% for $19 Billion. ATTR-CM is the heart condition treated with other stabilizers that failed in Phase 3 trial. Has Vascepa been in clinical trials for that condition?

A good 2:13m video in link...

https://x.com/SanCompounding/status/2074871489476878370

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

https://linktw.in/UQjike

AZN major clinical trial failure/setback with gene-silencing Wainua drug partnered with IONS.  AZN stock drops ~ $19 Billion. Bloomberg news is source.